A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study

Journal of Cancer Research and Clinical Oncology

Volumn 141, Issue 1, 2015, Pages 153-160

  Yasui, Hirofumi ^a   Muro, Kei ^b   Shimada, Yasuhiro ^c   Tsuji, Akihito ^d   Sameshima, Shinichi ^e   Baba, Hideo ^f   Satoh, Taroh ^g   Denda, Tadamichi ^h   Ina, Kenji ⁱ   Nishina, Tomohiro ^j   Yamaguchi, Kensei ^k   Esaki, Taito ^l   Tokunaga, Shinya ^m   Kuwano, Hiroyuki ⁿ   Boku, Narikazu ^o   Komatsu, Yoshito ^p   Watanabe, Masahiko ^q   Hyodo, Ichinosuke ^r   Morita, Satoshi ^s   Sugihara, Kenichi ^t  

^a SHIZUOKA CANCER CENTER   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

^e DOKKYO MEDICAL UNIVERSITY   (Japan)

^f KUMAMOTO UNIVERSITY   (Japan)

^g OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^h CHIBA CANCER CENTER   (Japan)

ⁱ Nagoya Memorial Hospital   (Japan)

^j NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^k SAITAMA CANCER CENTER   (Japan)

^l NATIONAL KYUSHU CANCER CENTER   (Japan)

^m OSAKA CITY GENERAL HOSPITAL   (Japan)

ⁿ GUNMA UNIVERSITY   (Japan)

^o ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^p HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^q KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^r UNIVERSITY OF TSUKUBA HOSPITAL   (Japan)

^s YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^t TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

more..

Author keywords

Colorectal cancer; FIRIS; Irinotecan; IRIS; S 1

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG COMBINATION; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OTERACIL; OXALIPLATIN; PLATINUM COMPLEX; S 1 (COMBINATION); TEGAFUR;

ADENOCARCINOMA; AGED; ANALOGS AND DERIVATIVES; CANCER STAGING; CLINICAL TRIAL; COLORECTAL NEOPLASMS; CONTROLLED STUDY; DRUG COMBINATION; FEMALE; FOLLOW UP; HUMAN; MALE; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SECONDARY; SURVIVAL RATE;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DRUG COMBINATIONS; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LEUCOVORIN; MALE; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; OXONIC ACID; PROGNOSIS; SURVIVAL RATE; TEGAFUR;

EID: 84925022373     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-014-1783-3     Document Type: Article

References (17)

1. Baba H, Watanabe M, Okabe H et al (2012) Upregulation of ERCC1 and DPD expressions after oxaliplatin-based first-line chemotherapy for metastatic colorectal cancer. Br J Cancer 107:1950–1955
2. Brookmeyer R, Crowley J (1982) A confidence interval for the median survival time. Biometrics 38:29–41
3. Fuse N, Doi T, Ohtsu A et al (2008) Safety of irinotecan and infusional fluorouracil/leucovorin (FOLFIRI) in Japan: a retrospective review of 48 patients with metastatic colorectal cancer. Int J Clin Oncol 13:144–149
4. Goto A, Yamada Y, Yasui H et al (2006) Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer. Ann Oncol 17:968–973
5. Komatsu Y, Yuki S, Fuse N et al (2010) Phase 1/2 clinical study of irinotecan and oral S-1 (IRIS) in patients with advanced gastric cancer. Adv Ther 27:483–492
6. Komatsu Y, Yuki S, Sogabe S et al (2011) Phase II study of combined treatment with irinotecan and S-1 (IRIS) in patients with inoperable or recurrent advanced colorectal cancer (HGCSG0302). Oncology 80:70–75
7. Muro K, Boku N, Shimada Y et al (2010) Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). Lancet Oncol 11:853–860
8. National Comprehensive Cancer Network (2014a) NCCN Clinical Practice Guidelines in Oncology: Colon Cancer, version 3.2014. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed May 20 2014
9. National Comprehensive Cancer Network (2014b) NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer, version 3.2014. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed May 20 2014
10. O’Neil BH, Goldberg RM (2008) Innovations in chemotherapy for metastatic colorectal cancer: an update of recent clinical trials. The Oncol 13:1074–1083
11. Peeters M, Price TJ, Cervantes A et al (2010) Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 28:4706–4713
12. Schmoll HJ, Van Cutsem E, Stein A et al (2012) ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol 23:2479–2516
13. Shiozawa M, Akaike M, Sugano N et al (2010) A phase II study of combination therapy with irinotecan and S-1 (IRIS) in patients with advanced colorectal cancer. Cancer Chemother Pharmacol 66:987–992
14. Sobrero AF, Maurel J, Fehrenbacher L et al (2008) EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 26:2311–2319
15. Spiegelhalter DJ, Freedman LS, Parmar MKB (1994) Bayesian approaches to randomized trials. J R Stat Soc 157:357–387
16. Tournigand C, André T, Achille E et al (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22:229–237
17. Tsunoda A, Yasuda N, Nakao K et al (2009) Phase II study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer. Oncology 77:192–196